BNP Paribas Arbitrage SA increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 448.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,489 shares of the biotechnology company’s stock after buying an additional 5,306 shares during the period. BNP Paribas Arbitrage SA’s holdings in Sarepta Therapeutics were worth $219,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of SRPT. BlackRock Inc. boosted its holdings in Sarepta Therapeutics by 4,403.1% in the 1st quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after buying an additional 5,175,193 shares during the period. Camber Capital Management LLC bought a new position in Sarepta Therapeutics in the 1st quarter worth $39,960,000. State Street Corp boosted its holdings in Sarepta Therapeutics by 21.2% in the 1st quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after buying an additional 559,342 shares during the period. Elk Creek Partners LLC boosted its holdings in Sarepta Therapeutics by 77.8% in the 1st quarter. Elk Creek Partners LLC now owns 562,522 shares of the biotechnology company’s stock worth $16,651,000 after buying an additional 246,059 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Sarepta Therapeutics by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 4,096,486 shares of the biotechnology company’s stock worth $121,256,000 after buying an additional 176,966 shares during the period. 65.41% of the stock is owned by institutional investors.

In other Sarepta Therapeutics news, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $410,000.00. Following the transaction, the director now directly owns 62,471 shares of the company’s stock, valued at $2,561,311. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of Sarepta Therapeutics stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the transaction, the senior vice president now directly owns 27,312 shares in the company, valued at $1,173,596.64. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock worth $3,224,208 over the last ninety days. 9.60% of the stock is owned by insiders.

Shares of Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 45.17 on Friday. The company has a 50-day moving average of $40.10 and a 200-day moving average of $34.92. Sarepta Therapeutics, Inc. has a 52-week low of $26.26 and a 52-week high of $63.73. The stock’s market capitalization is $2.91 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same period last year, the firm earned ($1.19) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post ($1.23) EPS for the current year.

Several research analysts recently weighed in on SRPT shares. Oppenheimer Holdings, Inc. set a $76.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Thursday, June 8th. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 18th. Leerink Swann reaffirmed a “buy” rating and issued a $60.00 target price (up previously from $52.00) on shares of Sarepta Therapeutics in a report on Tuesday, July 18th. Finally, ValuEngine raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Nine equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $62.42.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/24/sarepta-therapeutics-inc-srpt-position-lifted-by-bnp-paribas-arbitrage-sa.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.